HK inno.N Corporation
CompanySouth Korea
HK inno.N Corporation develops 3 assets, the furthest approved (aspirin). Mostly small molecule acting on lipid and ceramide metabolism, AMPK signalling and HMGCR; based in South Korea.
- 3
- Assets
- Furthest
- Approved
- 33
- Trials
- 1
- Signal
Pipeline
3Irreversibly inhibits cyclooxygenase-1 and 2, decreasing prostaglandin and thromboxane synthesis
Approved, Small molecule, Lipid and ceramide metabolism, Inflammation, acute coronary syndrome (Phase 3), blood viscosity (Phase 3)
HMG-CoA reductase inhibitor that suppresses cholesterol biosynthesis and lowers plasma LDL levels
Approved, Small molecule, AMPK signalling, Lipid and ceramide metabolism, angina, coronary heart disease
Fixed-dose combination of atorvastatin (HMG-CoA reductase inhibitor) and metformin for metabolic control.
Phase 3, Small molecule, AMPK signalling, Lipid and ceramide metabolism, hyperlipidemia, hypertension
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms9
- Trials41
- Signals3
- Similar companies6
Updated 8 Oct 2026 · 134 sources